In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
about
"One-size-fits-all"? Optimizing treatment duration for bacterial infectionsExploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsIn vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?The population dynamics of antimicrobial chemotherapy.Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effectStudies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models.Nosocomial pneumonia : rationalizing the approach to empirical therapy.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.
P2860
Q28478851-6927E1C1-6ECC-4BA5-9E51-82CD615C56C8Q33767602-6AE988E9-B8E1-46E7-A08C-25398CEDF6E9Q34347908-EC1CA85C-94A8-40FE-8242-19FE0AAFE423Q35132378-2F454937-1881-431E-9FA6-1448C51507B8Q35136844-902383E3-D243-47DB-9B14-70A70DDCC690Q35212401-F52891DB-B135-44A4-BC4F-F2322825E2CAQ36366778-537F91F9-9A47-40F7-8588-AA51B34589F4Q37568933-09444901-133E-4A2C-9E11-2CDDA770EB6DQ38004063-68A3E3E1-8CFA-4E8E-AEC3-9320A4E6A4D5Q39471967-88CEDFDC-C23E-49A0-BD43-EA67AF381CFFQ39784317-45CC3B21-E986-4AA3-99DC-7047846C8974Q40666822-13DED568-615B-43B4-8D73-A419BF028EA8Q51932254-6E2AC200-DBF0-4AF0-881C-DC1D55D53B95
P2860
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@ast
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@en
type
label
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@ast
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@en
prefLabel
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@ast
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@en
P2093
P2860
P356
P1476
In vitro pharmacodynamics of p ...... e, and Pseudomonas aeruginosa.
@en
P2093
P2860
P304
P356
10.1128/AAC.39.8.1711
P407
P577
1995-08-01T00:00:00Z